US › Healthcare

Burning Rock Biotech Ltd (BNR)

US · Healthcare · Diagnostics & Research

$13.52+7.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$134.9M

Revenue YoY

-9.2%

Net profit

$-18.4M

EPS

$-0.20

Net margin

-13.7%

Key statistics

Market cap

$129.5M

Forward P/E

0.0

P/B

1.58

Book value

$7.32

EPS (TTM)

$-0.89

52-week high

$41.72

52-week low

$6.79

50-day MA

$9.85

200-day MA

$17.47

Beta

1.39

Analyst view

Analysts rate Burning Rock Biotech Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.03.

Shareholding

Insiders

4.01%

Institutions

46.97%

Largest institutional holders

Fund	Stake
Kynam Capital Management, LP	11.74%
CRCM LP	2.01%
Renaissance Technologies Corp	0.34%
Amova Asset Management Americas, Inc	0.29%
Sumitomo Mitsui Trust Group Inc	0.28%
Bank of America Corp	0.28%
HSG Holding Ltd	0.20%
Redwood Wealth Management Group LLC	0.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Burning Rock Biotech Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.